Los Angeles-based CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The company's oncology pipeline is focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin. The company also has rights to two additional drug candidates, tamibarotene and bafetinib.
At the helm of the company's strong management team is president and CEO Steven A. Kriegsman, who has held the post since 2002. He also serves as a director of Galena Biopharma, Inc. (NASDAQ:GALE) and chairman of Galena's Compensation and Transaction Committees. Kriegsman previously served as director and chairman of Global Genomics from June 2000.
Kriegsman also is an inactive chairman and founder of Kriegsman Capital Group LLC, a financial advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. He has advised such companies as SuperGen, Inc., Closure Medical Corporation, Novoste Corp., Advanced Tissue Sciences, and Maxim Pharmaceuticals.
Kriegsman has a BS degree with honors from New York University in Accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute. Kriegsman is a graduate of the Stanford Law School Directors' College. He was formerly a Certified Public Accountant with KPMG in New York City, and served as a director and is the former chairman of the Audit Committee of Bradley Pharmaceuticals, Inc..
In 2006, Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association, and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy Association. Kriegsman has been a guest speaker and lecturer at various universities including California Institute of Technology (Caltech), Brown University and New York University. He has also been active in various charitable organizations including the Biotechnology Industry Organization, the ALS Association, the Los Angeles Venture Association, the Southern California Biomedical Council, the California Health Initiative, the American Association of Dance Companies, and the Palisades-Malibu YMCA.
For more information, see the company website at cytrx.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com